LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

Home・Elenco Azioni・Cogent Biosciences Inc

Cogent Biosciences Inc

Chiusa

36.45 -1.46

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

36.35

Massimo

37.94

Metriche Chiave
By Trading Economics
Entrata	-22M -102M
EPS	-0.5
Dipendenti	258
EBITDA	-30M -109M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+40.99% upside

Dividendi
By Dow Jones
Utili prossimi	5 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	705M 6.3B
Apertura precedente	37.91
Chiusura precedente	36.45

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

4.88 / 5.87 Supporto e resistenza

Cogent Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 mar 2026, 20:38 UTC

Utili

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10 mar 2026, 23:57 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

10 mar 2026, 23:57 UTC

Discorsi di Mercato

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10 mar 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10 mar 2026, 23:37 UTC

Acquisizioni, Fusioni, Takeovers

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10 mar 2026, 23:37 UTC

Acquisizioni, Fusioni, Takeovers

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10 mar 2026, 23:37 UTC

Acquisizioni, Fusioni, Takeovers

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10 mar 2026, 23:37 UTC

Acquisizioni, Fusioni, Takeovers

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10 mar 2026, 23:35 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10 mar 2026, 23:06 UTC

Utili

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10 mar 2026, 22:51 UTC

Principali Notizie su Eventi

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10 mar 2026, 21:39 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10 mar 2026, 21:21 UTC

Utili

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10 mar 2026, 21:15 UTC

Utili

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10 mar 2026, 21:15 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10 mar 2026, 21:14 UTC

Utili

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10 mar 2026, 21:13 UTC

Utili

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10 mar 2026, 21:12 UTC

Utili

Franco-Nevada 4Q Rev $597.3M >FNV

10 mar 2026, 21:12 UTC

Utili

Franco-Nevada 4Q EPS $1.90

10 mar 2026, 20:57 UTC

Utili

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:50 UTC

Discorsi di Mercato

Utili

Tech, Media & Telecom Roundup: Market Talk

10 mar 2026, 20:44 UTC

Utili

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:34 UTC

Discorsi di Mercato

Utili

Global Equities Roundup: Market Talk

10 mar 2026, 20:34 UTC

Discorsi di Mercato

Utili

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10 mar 2026, 20:23 UTC

Utili

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:16 UTC

Utili

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10 mar 2026, 20:14 UTC

Utili

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10 mar 2026, 20:14 UTC

Utili

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10 mar 2026, 20:13 UTC

Utili

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10 mar 2026, 20:12 UTC

Utili

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Confronto tra pari

Modifica del prezzo

Cogent Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

40.99% in crescita

Previsioni per 12 mesi

Media 52.18 USD 40.99%

Alto 67 USD

Basso 35 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

4.88 / 5.87Supporto e resistenza

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.